London
· Delayed Price · Currency is GBP · Price in USD Moleculin Biotech Company Description
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.
Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers.
The company was incorporated in 2015 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 18 |
| CEO | Walter Klemp |
Contact Details
Address: 5300 Memorial Drive Houston, Delaware 77007 United States | |
| Phone | (713) 300-5160 |
| Website | moleculin.com |
Stock Details
| Ticker Symbol | 0K2H |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Walter Klemp | Chief Executive Officer |
| Jonathan Foster | Chief Financial Officer |